“Autosomal Dominant Polycystic Kidney Disease (ADPKD) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Autosomal Dominant Polycystic Kidney Disease Market.
The Autosomal Dominant Polycystic Kidney Disease Pipeline report embraces in-depth commercial, regulatory, and Autosomal Dominant Polycystic Kidney Disease clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Autosomal Dominant Polycystic Kidney Disease drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Autosomal Dominant Polycystic Kidney Disease (ADPKD) Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the emerging therapies for Autosomal Dominant Polycystic Kidney Disease treatment and the aggregate therapies developed by major pharma companies.
It accesses the different Autosomal Dominant Polycystic Kidney Disease therapies segmented into early-stage, mid-stage, and late-stage of clinical development.
It outlines the major Autosomal Dominant Polycystic Kidney Disease companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
The report evaluates the Autosomal Dominant Polycystic Kidney Disease drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Autosomal Dominant Polycystic Kidney Disease therapeutic market.
Autosomal Dominant Polycystic Kidney Disease (ADPKD) Therapeutics Landscape
At present, there is no curative treatment for ADPKD and most available treatments focus on managing the associated complications, delaying kidney function decline, and slowing the cyst enlargement. Angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARB) are preferred by most specialists who treat hypertension in ADPKD patients. In individuals with ADPKD, these drugs may be more effective in preserving kidney function and preventing left ventricular hypertrophy than other therapies for hypertension.
Effective treatment requires the coordinated efforts of a team of specialists working together to systematically and comprehensively plan an affected individual’s prescription. Such specialists may include primary care family physicians, pediatricians, or internists who collaborate with physicians specializing in disorders of the kidneys (nephrologists), surgical disorders of the urinary tract (urologists), dietitians, and/or other health care professionals. Genetic counseling may benefit affected individuals and their families.
Tolvaptan (Jynarque/Jinarc/Samsca) developed by Otsuka Pharmaceutical is the only FDA-approved therapy to treat adults with rapidly progressing ADPKD. With improved disease understanding to address the current unmet need for ADPKD, several companies like Reata Pharmaceuticals, Sanofi, Janssen Pharmaceuticals, and Regulus Therapeutics are conducting trials for molecules that target various pathways to control cyst formation or delay it.
There are approx. 12+ key companies developing therapies for Autosomal dominant polycystic kidney disease. Currently, Reata Pharmaceuticals is leading the therapeutics market with its Autosomal dominant polycystic kidney disease drug candidates in the most advanced stage of clinical development.
Autosomal Dominant Polycystic Kidney Disease (ADPKD) Companies Actively Working in the Therapeutic Market Include:
AceLink Therapeutics
Alebund Pharmaceuticals
Anakuria Therapeutics
Chinook Therapeutics
Galapagos NV
Healx
Janssen Pharmaceuticals
Kadmon Pharmaceuticals
Otsuka Pharmaceutical
Poxel
Reata Pharmaceuticals
Regulus Therapeutics
Sanofi
Xortx Therapeutics
And Many Others
Emerging and Marketed Autosomal Dominant Polycystic Kidney Disease (ADPKD) Drugs Covered in the Report Include:
GLPG2737: Galapagos NV
Bardoxolone methyl: Reata Pharmaceuticals
Jynarque/Jinarc/Samsca (tolvaptan): Otsuka Pharmaceutical
Tesevatinib/KD019: Sanofi
RGLS8429: Regulus Therapeutics
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Autosomal Dominant Polycystic Kidney Disease Companies Working in the Market @
https://www.delveinsight.com/sample-request/autosomal-dominant-polycystic-kidney-disease-pipeline-insight
Analysis of Emerging Autosomal Dominant Polycystic Kidney Disease Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued and inactive candidates
Route of Administration
Autosomal dominant polycystic kidney disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Inhalation
Inhalation/Intravenous/Oral
Intranasal
Intravenous
Intravenous/ Subcutaneous
Oral
Oral/intranasal/subcutaneous
Parenteral
Subcutaneous
Molecule Type
Products have been categorized under various Molecule types such as
Antibody
Antisense oligonucleotides
Immunotherapy
Monoclonal antibody
Peptides
Protein
Recombinant protein
Small molecule
Stem Cell
Vaccine
Learn How the Autosomal Dominant Polycystic Kidney Disease Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Autosomal Dominant Polycystic Kidney Disease Treatment Patterns
4. Autosomal Dominant Polycystic Kidney Disease – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Autosomal Dominant Polycystic Kidney Disease Late Stage Products (Phase-III)
7. Autosomal Dominant Polycystic Kidney Disease Mid-Stage Products (Phase-II)
8. Autosomal Dominant Polycystic Kidney Disease Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Autosomal Dominant Polycystic Kidney Disease Discontinued Products
13. Autosomal Dominant Polycystic Kidney Disease Product Profiles
14. Major Autosomal Dominant Polycystic Kidney Disease Companies in the Market
15. Key Products in the Autosomal Dominant Polycystic Kidney Disease Therapeutics Segment
16. Dormant and Discontinued Products
17. Autosomal Dominant Polycystic Kidney Disease Unmet Needs
18. Autosomal Dominant Polycystic Kidney Disease Future Perspectives
19. Autosomal Dominant Polycystic Kidney Disease Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
Diabetic Macular Edema (DME) Market
“Diabetic Macular Edema (DME) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Diabetic Macular Edema (DME) market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Diabetic Macular Edema (DME) market.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
